Sanofi ADR Accounts Payable Over Time
| SNY Stock | USD 48.72 0.44 0.91% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sanofi ADR Performance and Sanofi ADR Correlation. Sanofi |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.115 | Earnings Share 1.88 | Revenue Per Share 19.3565 | Return On Assets 0.0416 | Return On Equity 0.0582 |
The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Accounts Payable Analysis
Compare Sanofi ADR and related stocks such as AstraZeneca PLC ADR, Roche Holding, and GlaxoSmithKline PLC ADR Accounts Payable Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | 1.4 B | 9 B | 9.2 B | 10.4 B | 11.9 B | 11.7 B | 10.5 B | 11.6 B | 12.8 B | 14 B | 2.4 B | 2.8 B | 2.5 B | 3.3 B | 6.1 B |
| GSK | 57 M | 7.4 B | 8.1 B | 8.3 B | 8 B | 9.2 B | 12 B | 21 B | 14 B | 14.9 B | 4.4 B | 4.5 B | 3.9 B | 3.7 B | 5.1 B |
| MRK | 937.2 M | 2.5 B | 1.8 B | 2.3 B | 2.6 B | 2.5 B | 2.8 B | 3.1 B | 3.3 B | 3.7 B | 4.3 B | 4.6 B | 4.3 B | 3.9 B | 2.8 B |
| NVS | 1.1 B | 5 B | 5.6 B | 6.1 B | 5.4 B | 5.7 B | 4.9 B | 5.2 B | 5.6 B | 5.4 B | 5.4 B | 5.6 B | 5.1 B | 4.9 B | 4.2 B |
| BMY | 475 M | 2.6 B | 2.2 B | 2.6 B | 2.5 B | 1.6 B | 1.7 B | 2.2 B | 1.9 B | 2.4 B | 2.7 B | 2.9 B | 3 B | 3.3 B | 1.9 B |
| GILD | 300 K | 1.2 B | 1.3 B | 1.3 B | 955 M | 1.2 B | 1.2 B | 814 M | 790 M | 713 M | 844 M | 705 M | 905 M | 550 M | 518.2 M |
| AMGN | 8.5 M | 642 M | 905 M | 787 M | 1.2 B | 965 M | 917 M | 1.4 B | 1.2 B | 1.4 B | 1.4 B | 1.4 B | 1.6 B | 1.6 B | 1.7 B |
| ABBV | 356.8 M | 417 M | 556 M | 933 M | 881 M | 1.6 B | 1.4 B | 1.5 B | 1.5 B | 1.5 B | 2.3 B | 2.9 B | 2.9 B | 3.7 B | 3.9 B |
| JNJ | 622 M | 5.7 B | 5.8 B | 6.3 B | 7.6 B | 6.7 B | 6.9 B | 7.3 B | 7.5 B | 8.5 B | 9.5 B | 11.1 B | 9.9 B | 9.6 B | 5.4 B |
Sanofi ADR and related stocks such as AstraZeneca PLC ADR, Roche Holding, and GlaxoSmithKline PLC ADR Accounts Payable description
An accounting item on the balance sheet that represents Sanofi ADR obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Sanofi ADR are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.My Equities
My Current Equities and Potential Positions
Additional Tools for Sanofi Stock Analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.